Streetbeat News

Stock Prices

TLSI

TriSalus Life Sciences (NASDAQ:TLSI) reported a significant improvement in Q3 2023 with a 99.5% decrease in losses per share to $(0.13) from $(25.95) YoY. Sales also increased by 32.37% to $5.19M from $3.92M YoY.

Portfolio Pulse from totan@benzinga.com

November 14, 2023 | 1:02 pm

NVDA

Nvidia Corp. (NASDAQ:NVDA) is poised to extend its rally to a 10th consecutive session, with shares trading up in premarket on Tuesday. The stock's recent gains have been driven by optimism around artificial intelligence and the unveiling of new AI chips, the H200. Nvidia's performance has made it the top S&P 500 stock this year and a leader among major tech stocks. The company is set to report Q3 results on November 21, which could further influence the stock's trajectory.

Portfolio Pulse from Shanthi Rexaline

November 14, 2023 | 1:01 pm

TMO

Thermo Fisher Scientific has authorized a new $4 billion share repurchase program. This move is part of the company's capital allocation strategy and reflects its commitment to returning value to shareholders. The repurchase authorization does not have an expiration date and can be executed through open market purchases or privately negotiated transactions.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:01 pm

ACRS

Aclaris Therapeutics (NASDAQ:ACRS) has received a mix of bullish and indifferent analyst ratings over the last quarter, with no bearish ratings. The average 12-month price target for ACRS is $29.43, which is a significant increase from the previous target of $18.00. The high target is $43.00 and the low is $2.00. The increase in the average price target suggests a positive outlook from analysts.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

UEC

Uranium Energy (AMEX:UEC) has received positive ratings from analysts in the last quarter, with 3 bullish and 1 somewhat bullish rating. The average price target is $7.25, which is higher than the current price of $5.94, indicating a potential upside. The average price target has increased by 3.57% from the previous target of $7.00. Analysts typically review stocks each quarter and their ratings are based on company performance, financial statements, and insider communications.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

MBCN

Middlefield Banc Corp. (NASDAQ:MBCN) has appointed Ronald L. Zimmerly, Jr. as its new CEO, effective January 1, 2024. He will succeed James R. Heslop, II, who is retiring. Zimmerly is currently the President and Director of Middlefield and The Middlefield Banking Company. Heslop will also resign from the Board of Directors on December 31, 2023, and the Board will be reduced from 13 to 12 members.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:00 pm

AKRO

11 Wall Street analysts have recently provided their opinions on Akero Therapeutics (NASDAQ:AKRO), with an average price target of $52.27, which is significantly higher than the current price of $13.95. The consensus among these analysts is positive, with 4 bullish and 7 somewhat bullish ratings. However, this target represents an 18.15% decrease from the previous target of $63.86. Analysts' ratings are based on comprehensive analysis, including company data and industry trends.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

AYX

Alteryx (NYSE:AYX) has received 8 analyst ratings in the last quarter with an average price target of $45.0, representing an upside from the current price of $37.3. The ratings include 4 bullish, 1 somewhat bullish, 1 indifferent, and 2 somewhat bearish. Over the past month, the average price target has increased by 38.46%. Analysts typically review stocks quarterly or after major company updates, basing their ratings on financial predictions and company performance.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

ALLK

Barclays analyst Carter Gould has maintained an Underweight rating on Allakos (NASDAQ:ALLK) and reduced the price target from $2.5 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:59 pm

BUD

RLX

USFD

Three consumer staples stocks, US Foods Holding Corp. (USFD), Anheuser-Busch InBev SA/NV (BUD), and RLX Technology Inc. (RLX), are showing overbought signals with RSI values above 70. USFD reported strong Q3 sales and market share gains, BUD reported a 5% sales growth but missed estimates, and RLX posted upbeat Q3 earnings. All three stocks saw slight increases in their share prices on Monday.

Portfolio Pulse from Lisa Levin

November 14, 2023 | 12:58 pm